Phaseline

Targets › SOST

SOST (Sclerostin): drug programs, companies and trials

2 programs from 2 companies in 17 trials: 7 Phase 4, 5 Phase 3, 3 Phase 2, 2 Phase 1; Other, Neurology, Metabolic and endocrine; next expected readout Jan 2027.

Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation. (UniProt, Q9BQB4)

Open in Phaseline: the race on SOST, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AmgenRomosozumab
Sclerostin inhibitor
SOSTPhase 3Osteogenesis Imperfecta; Healthy Participants; Osteoporosis; Postmenopausal Osteoporosis …Jan 2027
Ultragenyx Pharmaceuticalsetrusumab
Sclerostin inhibitor
SOSTPhase 3Osteogenesis ImperfectaJan 2027

Conditions

Osteoporosis (6) Osteogenesis Imperfecta (5) Healthy Participants (1) Postmenopausal Osteoporosis (1) Osteoporosis, Postmenopausal (1) FHA (Functional Hypothalamic Amenorrhea) (1) Premenopausal Idiopathic Osteoporosis (1) Breast Cancer (1)

Modalities

antibody (2)

Companies

Amgen (1) Ultragenyx Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.